
Canadian trade minister says "we're prepared to stick around and do the work needed" after U.S. imposed 35% tariff on goods
"We believe there's a great deal of common ground between the United States and Canada in terms of building two strong economies that work well together," LeBlanc said on "Face the Nation with Margaret Brennan."
The White House announced last week that duties would jump from 25% to 35% on Canadian goods not covered under the Canada-United States-Mexico Agreement, claiming that the U.S.' second-largest trading partner hasn't done enough to address immigration and the flow of fentanyl into the U.S. LeBlanc said that while "we were obviously disappointed by that decision," negotiators would "continue to do the work."
LeBlanc said his team left with "a better understanding of the American concerns in the trading relationship" and characterizing the meetings with U.S. Trade Representative Jamieson Greer and Commerce Secretary Howard Lutnick as "constructive, cordial conversations."
"We're encouraged by the conversations with Secretary Lutnick and Ambassador Greer, but we're not yet where we need to go to get the deal that's in the best interest of the two economies," LeBlanc said.
Mr. Trump announced higher tariffs against more than 60 U.S. trading partners late last week. But Canada is the largest American trading partner included, being the world's largest buyer of American goods and the third-largest seller of goods to the U.S. last year, according to Census Bureau data. The country bought some $350 billion worth of American goods and sold $412 billion to the U.S. market in 2024.
In an interview for "Face the Nation" on Friday, Greer cited Canada's retaliatory tariffs imposed earlier this year under former Prime Minister Justin Trudeau for the increase, saying, "if the president's going to take an action and the Canadians retaliate, the United States needs to maintain the integrity of our action, the effectiveness, so we have to go up too."
"Our view is the president is trying to fix the terms of trade with Canada, and if there's a way to a deal, we'll find it," Greer said. "And if it's not, we'll have the tariff levels that we have."
In a statement released Friday, Canadian Prime Minister Mark Carney said he was "disappointed" by Mr. Trump's actions. He noted that "Canada accounts for only 1% of U.S. fentanyl imports and has been working intensively to further reduce these volumes."
On Sunday, LeBlanc said he expects Carney will have a conversation with Mr. Trump "over the next number of days," while noting that the Canadian prime minister has "built a very business-like, respectful relationship with President Trump."
"We understand and respect totally the president's view in terms of the national security interests. In fact, we share it," LeBlanc said. "And what we've said to our American counterparts is, how can we structure the right agreement where we can both continue to supply one another in a reliable, cost effective way that preserves jobs essential to the American economy? But the same thing is true, obviously in Canada as well."
The U.S.-Canada relationship has been strained since Mr. Trump came into office in January and repeatedly suggested that Canada could become the "51st state." Carney emphatically denied this in an Oval Office meeting with Mr. Trump in May, saying Canada is "not for sale."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
Calumet Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Explore Calumet's Fair Values from the Community and select yours Calumet (NASDAQ:CLMT) Second Quarter 2025 Results Key Financial Results Revenue: US$1.03b (down 9.4% from 2Q 2024). Net loss: US$147.9m (loss widened by 271% from 2Q 2024). US$1.70 loss per share (further deteriorated from US$0.49 loss in 2Q 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period Calumet Revenues Beat Expectations, EPS Falls Short Revenue exceeded analyst estimates by 8.3%. Earnings per share (EPS) missed analyst estimates significantly. Looking ahead, revenue is forecast to grow 3.9% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Oil and Gas industry in the US. Performance of the American Oil and Gas industry. The company's shares are down 7.4% from a week ago. Risk Analysis We should say that we've discovered 3 warning signs for Calumet (2 don't sit too well with us!) that you should be aware of before investing here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
2 minutes ago
- Yahoo
Emera Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Explore Emera's Fair Values from the Community and select yours Emera (TSE:EMA) Second Quarter 2025 Results Key Financial Results Revenue: CA$1.99b (up 23% from 2Q 2024). Net income: CA$154.0m (up 19% from 2Q 2024). Profit margin: 7.7% (down from 8.0% in 2Q 2024). The decrease in margin was driven by higher expenses. EPS: CA$0.52 (up from CA$0.45 in 2Q 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period Emera Revenues Beat Expectations, EPS Falls Short Revenue exceeded analyst estimates by 9.7%. Earnings per share (EPS) missed analyst estimates by 30%. Looking ahead, revenue is forecast to grow 1.4% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Electric Utilities industry in North America. Performance of the market in Canada. The company's shares are up 3.7% from a week ago. Risk Analysis Before you take the next step you should know about the 2 warning signs for Emera that we have uncovered. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 minutes ago
- Yahoo
Spectral Medical Second Quarter 2025 Earnings: CA$0.007 loss per share (vs CA$0.016 loss in 2Q 2024)
Explore Spectral Medical's Fair Values from the Community and select yours Spectral Medical (TSE:EDT) Second Quarter 2025 Results Key Financial Results Revenue: CA$813.0k (up 73% from 2Q 2024). Net loss: CA$1.93m (loss narrowed by 56% from 2Q 2024). CA$0.007 loss per share (improved from CA$0.016 loss in 2Q 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period Spectral Medical Earnings Insights Looking ahead, revenue is forecast to grow 72% p.a. on average during the next 3 years, compared to a 66% growth forecast for the Biotechs industry in Canada. Performance of the Canadian Biotechs industry. The company's shares are down 1.2% from a week ago. Risk Analysis Be aware that Spectral Medical is showing 4 warning signs in our investment analysis and 3 of those are significant... Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.